Boehringer Ingelheim

Boehringer Ingelheim booth at AACR 2026

Biotech

Boehringer bags viral vector platform for cancer vaccine R&D

Boehringer Ingelheim has landed an exclusive license to Prime Vector’s viral vector platform for developing next-generation cancer vaccines.

Nick Paul Taylor Jul 7, 2026 10:35am

Robotic hand stacking coins

With $15M, BI becomes latest to buy into Immunai’s AI platform

Jun 25, 2026 9:00am

lung cancer

Guardant Health nabs FDA test approval for BI's new cancer drug

Jun 12, 2026 9:47am

Boehringer Ingelheim ADA2026 BI

ADA: Tolerability questions linger for Boehringer's obesity drug

Jun 8, 2026 4:30am

Berlin Germany Brandenburg Gate

Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm

Three blocks displaying from left to right a person a handshake and another person

Boehringer makes €407M bet on Immunitas’ inflammatory asset

May 12, 2026 9:57am